Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.64 |
| ▸ | MAOB | P27338 | 9/20 | 0.62 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.62 |
| ▸ | APP | P05067 | 1/20 | 0.57 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.55 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | CA7 | P43166 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | GSK3B | P49841 | 1/20 | 0.51 |
| ▸ | BACE1 | P56817 | 1/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3500162 | 0.85 | NR4A2 (0.71) | NR4A2MAOBPARP10APPHRH3 | |
| SCHEMBL224149 | 0.85 | ALOX5 (0.65) | NR4A2MAOBPARP10HRH3S1PR5 | |
| SCHEMBL108765 | 0.84 | GAA (0.53) | — | |
| SCHEMBL27550091 | 0.82 | MAOB (0.80) | NR4A2MAOBPARP10APPCA12 | |
| SCHEMBL5090748 | 0.81 | MAOB (0.63) | NR4A2MAOBPARP10APPCA12 | |
| SCHEMBL12687883 | 0.81 | MMP1 (0.64) | NR4A2MAOBPARP10APPCA12 | |
| SCHEMBL2088391 | 0.80 | MAOB (0.44) | NR4A2MAOBPARP10FFAR1 | |
| SCHEMBL11601115 | 0.78 | MAOB (0.69) | NR4A2MAOBPARP10APPCA12 | |
| SCHEMBL3618029 | 0.78 | MAOB (0.69) | NR4A2MAOBPARP10APPCA12 | |
| SCHEMBL6412631 | 0.78 | NR4A2 (1.00) | NR4A2MAOBPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | NR4A2 32/4885MAOB 3606/4885PARP10 1500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.